Autoimmune focus Opportunity to engage HotSpot Therapeutics on autoimmune disease programs, such as lupus, where their HST-2011 oral allosteric candidate may align with strategic partnerships or co-development discussions to accelerate clinical progress.

Oral small molecules Position their oral, allosteric small molecules as a differentiator for customers seeking targeted, high-selectivity therapies with favorable pharmacology. Explore collaborations with companies needing asset diversification beyond active-site inhibitors.

Regulatory hotspots Leverage HotSpot’s platform of targeting natural regulatory pockets to identify potential combinatorial strategies with existing therapies, enabling enhancement of efficacy or resistance profiling in partner programs.

Clinical leadership With a new Chief Medical Officer appointment, there is an opening to pitch senior strategic discussions, potential advisory or leadership roles in trial design, endpoints, and regulatory strategy to advance key assets.

Rheumatology presence capitalize on recent conference activity around EULAR and lupus programs to pursue sponsored research, licensing, or milestone-driven partnerships with rheumatology-focused biotech or pharma companies seeking novel mechanisms.